Eloxx Pharmaceuticals (NASDAQ:ELOX) Rating Increased to Strong-Buy at Lucid Cap Mkts

Eloxx Pharmaceuticals (NASDAQ:ELOX) was upgraded by analysts at Lucid Cap Mkts to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other equities analysts have also commented on ELOX. Weiss Ratings initiated coverage on shares of Eloxx Pharmaceuticals in a report on Friday, August 14th. They issued a “sell (d)” rating on the stock. Wall Street Zen raised shares of Eloxx Pharmaceuticals to a “hold” rating in a report on Saturday, August 1st. Lifesci Capital started coverage on shares of Eloxx Pharmaceuticals in a research report on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 target price for the company. Finally, Guggenheim assumed coverage on Eloxx Pharmaceuticals in a research note on Monday, July 20th. They issued a “buy” rating and a $43.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $41.50.

Eloxx Pharmaceuticals Trading Up 16.3%

Shares of ELOX opened at $20.98 on Thursday. The company has a market cap of $84.76 million, a P/E ratio of -13.62 and a beta of -1,864.08. The firm’s 50-day simple moving average is $14.32. Eloxx Pharmaceuticals has a 12-month low of $8.20 and a 12-month high of $23.40.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.